China is changing the world's pharma landscape, with Ruby Wang and Alexander Brown
China's transformation in biotech and drug development in the last two decades has been dramatic. It has moved from featuring many copycats or generics based on Western assets to now increasingly being a source of novel, high-quality drug assets. Ruby Wang, writer, physician, and biotech consultant, and Alexander Brown, Lead Analyst at MERICS, join Johannes Heller-John to discuss China’s rise in the biotech sector, and what it means for companies, decisionmakers and patients in China and Europe.
Learn more about the topics in this issue here:
- China Cure: The Rise of a Biotech, AI Medicine and Global Health Superpower, by Ruby Wang
- Lab leader, market ascender: China's rise in biotechnology, by Alexander Brown and Jeroen Groenewegen-Lau
